Arecor, backed by Unilever Ventures, aims to pioneer and develop dramatically better delivery forms for proteins & biological therapies.Find out more
By applying science of the highest calibre Arecor uncovers new insights in protein chemistry, enabling development of differentiating next generation biologics.
The Arecor technology has a demonstrated potential to significantly improve the stability of complex biologicals by using novel formulation design principles.
Arecor has transformed the development paths and delivery options for a wide range of new therapeutic products by working closely with partner companies to employ their suite of rationally-derived stabilisation technologies.
Arecor’s biologic stabilisation technology provided the stabilisation breakthrough needed for commercialisation of Oxyzyme and Iodozyme, Archimed's unique wound healing products.